BlueRock Therapeutics
↗Cambridge, USA
BlueRock Therapeutics is a leading clinical-stage cell therapy company focused on creating cellular medicines to treat devastating diseases. The company utilizes its proprietary induced pluripotent stem cell (iPSC) platform to engineer and manufacture 'off-the-shelf' cell therapies that replace or repair damaged tissue. Their primary focus areas include neurology, cardiology, and immunology.
Founded in 2016 as a joint venture between Versant Ventures and Leaps by Bayer, BlueRock was acquired by Bayer AG in 2019 for approximately $600 million. It now operates as a wholly owned but independently managed subsidiary within Bayer's Cell & Gene Therapy platform. The company is headquartered in Cambridge, MA, with additional research and manufacturing sites in New York and Toronto.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:Clinical Stage
Founded:2016
Ownership:subsidiary
Status:operating
FUNDING
Stage:Acquired
Total Raised:$225M
Investors:Versant Ventures, Leaps by Bayer
STOCK
Exchange:ETR
Ticker:BAYN
Market Cap:$30B+
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Cell therapy, iPSC-derived cells, Gene-edited cell therapy
Active Trials:4
Trial Phases:Phase 1: 2 | Phase 2: 1 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Bayer AG
Acquired By:Bayer AG (2019-08-01)
Key Partnerships:FUJIFILM Cellular Dynamics (iPSC manufacturing), Opsis Therapeutics (Ophthalmology collaboration), Editas Medicine (CRISPR gene editing), Senti Biosciences (Gene circuits)
COMPETITION
Position:Leader
Competitors:Fate Therapeutics, Aspen Neuroscience, Sana Biotechnology, Be Biopharma, Century Therapeutics
LEADERSHIP
Key Executives:
Seth Ettenberg - CEO
Amit Rakhit - Chief Development and Medical Officer
Stefan Irion - Chief Scientific Officer
Scientific Founders:Lorenz Studer, Viviane Tabar, Gordon Keller
Board Members:Jerel Davis (Versant Ventures), Juergen Eckhardt (Leaps by Bayer)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with BlueRock Therapeutics. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.